<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784157</url>
  </required_header>
  <id_info>
    <org_study_id>7222</org_study_id>
    <nct_id>NCT03784157</nct_id>
  </id_info>
  <brief_title>Study Of The Metabolic Parameters Of Uterine Muscle Cells</brief_title>
  <official_title>Study Of The Metabolic Parameters Of Uterine Muscle Cells In Cold Ischemia From Hysterectomies Programmed For Benign</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, no transplant has allowed pregnancy from a donor in a state of brain death. One of
      the main reservations lies in the ischemic properties of the uterine graft between the
      sampling time and the grafting time.

      Investigators propose to carry out a prospective monocentric study at the University
      Hospitals of Strasbourg in 2018/2019: the objective would be to study physiologically the
      time of ischemia of the uterine muscle The objective is to carry out a preparatory study on
      healthy uteri to study the ischemic properties of uterine muscle from living markers: study
      of mitochondrial respiration and free radical production on uterine muscle samples If the
      markers are reliable, they would then be used to measure the ischemia of whole uteri
      collected at the end of the multi-organ retrieval process from donors in a state of brain
      death and stored in tissue survival media.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemia</measure>
    <time_frame>1 hour after sampling</time_frame>
    <description>Study physiologically the time of ischemia of the uterine muscle 1 hour after sampling</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ischemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient benefiting from the routine management of a programmed hysterectomy by vaginal,
        laparoscopic or laparotomy for benign pathologies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  - Adult patient

          -  Patient benefiting from the routine management of a programmed hysterectomy by
             vaginal, laparoscopic or laparotomy for benign pathologies (fibroma, adenomyosis,
             genital prolapse,...) within the CMCO

          -  Patient consenting to the use of cells from her uterus for incineration for research
             purposes

          -  Patient giving her consent for the use of her medical data for the purposes of this
             research.

          -  Patient agreeing to participate in the study

        Exclusion criteria:

          -  - Patient refusing to participate in the study

          -  Patient under the protection of justice

          -  Patient under guardianship or curatorship

          -  Suspicion of gynaecological malignant pathology

          -  Pregnant or breastfeeding woman

          -  Impossibility to give the subject informed information (difficulties in understanding
             the subject...)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Olivier GARBIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier GARBIN, MD</last_name>
    <phone>33 3 69 55 34 04</phone>
    <email>olivier.garbin@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde PELISSIE, MD</last_name>
    <phone>33 3 69 55 34 04</phone>
    <email>mathilde.pelissie@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Gyn√©cologie - CMCO</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GARBIN, MD</last_name>
      <phone>33 3 69 55 34 04</phone>
      <email>olivier.garbin@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mathilde PELISSIE, MD</last_name>
      <phone>33 3 69 55 34 04</phone>
      <email>mathilde.pelissie@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier GARBIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde PELISSIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard GENY, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline HOST, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel HUMMEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor GABRIELE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Laure CHARLES, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>December 21, 2018</last_update_submitted>
  <last_update_submitted_qc>December 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hysterotomy</keyword>
  <keyword>UTERINE MUSCLE CELLS</keyword>
  <keyword>ISCHEMIA</keyword>
  <keyword>COLD ISCHEMIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

